Gossamer Bio GOSS 深 沪
等待开盘 08-28 09:30:00 美东时间
0.1701
-0.004
-2.19%
华盛通- 最 高0.1779
- 今 开0.1761
- 成交量 1543.68万股
- 最 低 0.163
- 昨 收 0.1739
- 总市值 8315.28万
- 52周最高 3.87
- 市盈率 静 --
- 换手率 3.16%
- 52周最低 0.1138
- 委 比 86.55%
- 总股本 4.89亿
- 历史最高 27.15
- 量 比 0.29
- 振 幅 8.57%
- 历史最低 0.1138
- 每 手 1
- 风险率 1.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Gossamer Bio announces up to $250M private placement
Gossamer Bio (GOSS) announced on Friday a private placement expected to provide up to approximately $250M in gross proceeds. The financing includes $150M of committed capital, with approximately $25M ...
08-21 21:19
Gossamer Bio Secures Major Seralutinib Regulatory Financing Deal
Gossamer Bio ( ($GOSS) ) has shared an announcement. On August 20, 2026, Gossam...
08-21 20:29
美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价
今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元
08-17 13:37
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4
Piper Sandler analyst Yasmeen Rahimi maintains Gossamer Bio (NASDAQ:GOSS) with a Overweight and lowers the price target from $15 to $4.
08-15 00:35
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M Estimate
Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.12) by 33.33 percent. This is a 52.94 percent increase over losses of $(0.17) per share from the same period last year. The company reported quarterly sales of $9.238 million wh...
08-14 04:18
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
美股大行评级 | ITG、Bending Spoons获多家大行首予买入评级；瑞银下调微软目标价从510美元降至480美元
今日重点评级关注：BTIG：上调Outlook Therapeutics"买入"评级，目标价4美元；TD Cowen：维持Nakamoto"买入"评级，目标价从1美元升至17美元
07-28 11:34
Gossamer Bio获FDA积极反馈，计划9月提交PAH新药上市申请
临床阶段生物制药公司Gossamer Bio今日宣布了一系列监管、战略及公司层面的重大更新。在与美国FDA进行卓有成效的Pre-NDA Type B会议并收...
07-27 21:56
Gossamer Bio Secures Stockholders Approval For Proposals Related To Convertible Note Exchange And Reverse Stock Split; Reports $57M Cash Position
Special Meeting: Approval of Proposals Related to Convertible Note Exchange and Reverse Stock Split At a special meeting held on July 14, 2026, Gossamer’s stockholders approved the proposals related to the previously completed exchange of its 5.00% Convertible Senior Notes due 2027 (the "2027 Notes"...
07-27 19:04
Gossamer Bio Advances Seralutinib Toward NDA In September 2026, Reacquires Global Rights To Seralutinib From Chiesi
– Pre-NDA Type B Meeting and FDA Minutes Provide Path to September 2026 NDA Submission for Seralutinib in PAH – – Gossamer Reacquires Worldwide Rights to Seralutinib, Aligning Global Commercial Control for a Potential First-in-Class Opportunity – – Stockholders Approved Proposals Related to Converti...
07-27 19:02
